350797-56-7 Silodosin Intermediates Puity NLT 98.0% Off White to Pale Brown

350797-56-7 Silodosin Intermediates Purity NLT 98.0% Appearance Powder

Chemical Name: 1 - ( 3 - ( Benzoyloxy ) propyl ) - 2,3 - dihydro - 5 - ( 2 - nitropropyl ) - 1H - indole - 7 -carbonitrile 

CAS No. 350797-56-7

Synonyms : 3 - ( 7 - Cyano - 5 - ( 2 - nitropropyl  )indolin - 1 - yl ) propyl benzoate ; 1 - [ 3 - ( Benzoyloxy ) propyl ] - 2 , 3 - dihydro - 5 - ( 2 - nitropropyl ) - 1H - indole - 7 - carbonitrile

Molecular Formula : C22H23N3O4

Molecular Weight : 393.443

Usuage: Silodosin Intermediate

Specifications:

Appearance: Almost White to pale brown yellow powder

Loss on drying: NMT 0.5%

Sulfated ash: NMT 0.2%

Total impurities: NMT 2.0%

Purity: NLT 98.0%

Description:

Silodosin is the active pharmaceutical ingredient (API) of branded drug Rapaflo in US, Silodyx in Europe and South Africa and Urief in Japan. It was first approved in Japan in 2006 and marketed by Kissei Pharmaceutical Co., Ltd and Daiichi Sankyo Pharaceutical Co., Ltd. It was also approved by FDA in USA in 2008. It is used for treating the signs and symptoms of benign prostatic hyperplasia, also called BPH. It can relax muscles in the prostate and bladder and so help to improve urine flow and reduce symptoms of benign prostatic hyperplasia.

1-[3-(BENZOYLOXY)PROPYL]-2,3-DIHYDRO-5-(2-NITROPROPYL)-1H-INDOLE-7-

CARBONITRILE CAS No. 350797-56-7 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are might be protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.